Assessment of NGAL, eGFR, and tubular injury markers for early detection of chemotherapy-induced nephrotoxicity in pediatric oncology patients.
The record presents the rationale for assessing NGAL, eGFR, and tubular injury markers to detect chemotherapy-associated kidney injury earlier than creatinine or oliguria in pediatric oncology patients, but provides no study methods or results.
Open original publication →What the AI sees
The record presents the rationale for assessing NGAL, eGFR, and tubular injury markers to detect chemotherapy-associated kidney injury earlier than creatinine or oliguria in pediatric oncology patients, but provides no study methods or results.
Research significance
The supplied abstract supports that drug-induced nephrotoxicity is often tubular, non-oliguric, and potentially missed by serum creatinine; it can therefore be hypothesized—but is not demonstrated here—that NGAL or other tubular markers could enable earlier treatment modification or supportive care and reduce renal toxicity.
Source abstract
Acute kidney injury is a common complication in children with oncological diseases. Its etiology is multifactorial, with key risk factors including drug-induced nephrotoxicity, tumor lysis syndrome, and infection-including sepsis during periods of aplasia. The classical diagnostic criteria for AKI rely on monitoring serum creatinine levels and detecting oliguria. In the context of drug-induced nephrotoxicity, the predominant pathophysiological mechanism is tubular injury, which is typically non-oliguric and may not cause changes in serum creatinine, even in cases of severe damage.